Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.385 EUR | +1.90% | +2.34% | -5.43% |
04-29 | Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3% | MT |
03-14 | Clinuvel Pharmaceuticals Launches Share Buyback Program | MT |
Sales 2024 * | 89.47M 59.87M 55.07M 81.42M | Sales 2025 * | 98.61M 65.99M 60.69M 89.73M | Capitalization | 774M 518M 476M 704M |
---|---|---|---|---|---|
Net income 2024 * | 34M 22.75M 20.93M 30.94M | Net income 2025 * | 37M 24.76M 22.77M 33.67M | EV / Sales 2024 * | 6.56 x |
Net cash position 2024 * | 187M 125M 115M 170M | Net cash position 2025 * | 219M 147M 135M 200M | EV / Sales 2025 * | 5.62 x |
P/E ratio 2024 * |
22.5
x | P/E ratio 2025 * |
20.8
x | Employees | - |
Yield 2024 * |
0.44% | Yield 2025 * |
0.48% | Free-Float | 79.52% |
Latest transcript on Clinuvel Pharmaceuticals Limited
1 day | +1.90% | ||
1 week | +2.34% | ||
Current month | +4.39% | ||
1 month | +2.23% | ||
3 months | -0.81% | ||
6 months | -10.53% | ||
Current year | -5.43% |
Managers | Title | Age | Since |
---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 05-10-31 |
Darren M. Keamy
DFI | Director of Finance/CFO | - | 05-10-31 |
Lachlan Hay
COO | Chief Operating Officer | - | 06-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 05-10-31 |
Director/Board Member | - | 07-02-05 | |
Karen Agersborg
BRD | Director/Board Member | - | 18-01-28 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 9.385 | +1.90% | 300 |
24-05-16 | 9.21 | -0.43% | 250 |
24-05-15 | 9.25 | -1.91% | 350 |
24-05-14 | 9.43 | +1.34% | 100 |
24-05-13 | 9.305 | +0.87% | 1,596 |
Delayed Quote Deutsche Boerse AG, May 17, 2024 at 02:14 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.32% | 92.59B | |
+3.68% | 41.43B | |
-10.90% | 33.49B | |
-19.56% | 14.62B | |
-9.06% | 12.77B | |
-11.34% | 11.58B | |
-43.53% | 11.35B | |
+3.75% | 8.97B | |
-6.32% | 8.3B |
- Stock Market
- Equities
- CUV Stock
- UR9 Stock